查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
全球數字糖尿病管理市場-2022-2029
市場調查報告書
商品編碼
1140718

全球數字糖尿病管理市場-2022-2029

Global Digital Diabetes Management Market - 2022-2029
出版日期: | 出版商: DataM Intelligence | 英文 180 Pages | 商品交期: 約2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

市場概況

數字糖尿病管理市場規模預計將在 2021 年達到 118.4 億美元，到 2029 年達到 297.6 億美元，在預測期間（2022-2029 年）以 13.65% 的複合年增長率增長。

糖尿病是一種由高血糖引起的代謝性疾病。它的發生是因為胰腺要麼不能產生足夠的胰島素，要麼身體不能有效地利用胰島素。它的特點是口渴和排尿增加、飢餓感增加、疲勞、視力模糊、腿和手麻木、持續疼痛和無法解釋的體重減輕。據說肥胖、高血壓、心髒病、抑鬱症和缺乏運動會增加患糖尿病的風險。數字糖尿病管理系統用於通過降低和維持低血糖水平來改善自我管理和控製糖尿病。

市場動態

由於糖尿病患者患病率上升等因素，全球數字糖尿病管理市場正在增長，老年人口不斷增加，久坐不動的生活方式，肥胖和新技術進步推動了市場增長。

糖尿病患病率的上升和各種新技術的進步預計將推動市場增長。

糖尿病患者患病率的上升，以及老年人口、久坐不動的生活方式和肥胖症的增加，將推動市場增長。根據國際糖尿病聯合會的數據，全世界約有 4.63 億 20-79 歲的成年人患有糖尿病。預計到 2045 年，這一數字將增加到 7 億。

市場繼續看到新的數字糖尿病藥物的推出和批准。例如，2022 年 5 月，Roche diabetes care推出了 Accu-Fine，這是一種筆形針頭，可實現平穩、幾乎無痛的胰島素給藥。它旨在通過使糖尿病患者更容易使用胰島素來改善糖尿病管理。

2022 年 6 月， Abbott正在開發一種新的生物儀器，該儀器將通過一個傳感器持續監測葡萄糖和酮水平。該系統已獲得美國 FDA 的突破性設備指定，將使危及生命的人們的生活更加舒適。

該市場以技術先進的產品為主，例如連續血糖監測儀、結合泵和監測儀以算法實現胰島素給藥自動化的系統、遠程醫療患者護理產品和人工胰腺。例如，在 2021 年 2 月，Medtronic的 InPen 智能胰島素筆和 Guardian 4 將獲得 CE 標誌，該傳感器是一種不需要手指棒來做出糖尿病治療決定的傳感器，還將獲得 CE 標誌。已宣布。這允許傳感器與 InPen 和 MiniMed 780G 集成，用於連續血糖監測。

糖尿病管理產品的高成本阻礙了市場增長

市場受到數字糖尿病管理產品高價的阻礙，例如智能手機連接的胰島素泵、基於傳感器的連續血糖儀和數字自我監測設備。此外，一些國家存在不利的報銷方案也將阻礙市場增長。報銷政策的差異，特別是在印度和中國等新興國家，往往導致治療不依從。

行業分析

全球數字糖尿病管理市場根據波特五力、監管分析、供應鏈分析和定價分析等各種行業因素對市場進行了深入分析。

細分分析

產品和服務部門在數字糖尿病管理全球市場中佔據最大市場份額

全球數字糖尿病管理市場按產品/服務類型細分為設備、數字糖尿病管理應用程序、數據管理軟件和平台以及服務。設備部分佔據了最高的市場份額。設備部分包括智能血糖儀、連續血糖監測（CGM）系統、智能胰島素筆、智能胰島素泵/閉環泵、智能胰島素貼片等。由於與智能設備的兼容性，連續血糖監測系統佔有最高的市場份額。由於與用作顯示設備的智能設備兼容，我們的連續血糖監測系統佔據了近 40.0% 的最大市場份額。它還可以設置為在達到某些葡萄糖閾值時向患者發送自定義警報。連續血糖監測設備使用插入皮下的傳感器。血糖讀數每 1-5 分鐘會出現在顯示器上。該設備允許在達到某些葡萄糖閾值時向患者發送自定義警報。該市場主要由美國食品和藥物管理局 (FDA) 批准的產品的可用性主導，例如DexCom G4 Platinum、Medtronic Diabetes Guardian Real-Time、Medtronic Diabetes MiniMed Paradigm Real-Time Revel，它們是連續血糖監測儀和胰島素泵。 .

由於開發智能胰島素筆的公司太多，預計智能胰島素筆細分市場將出現積極的市場增長。智能胰島素筆的推出正在興起。例如，2020 年 11 月，Medtronic在收購 Companion Medical 後推出了與公司 Guardian Connect 血糖監測系統集成的 InPen 設備。InPen 是第一個也是唯一一個獲得 FDA 批准的解決方案，包括一個胰島素注射器筆、一個直觀的智能手機應用程序和一個使用藍牙技術的推注顧問。可用於胰島素劑量跟蹤，包括啟動。它還自動將數據發送到用戶的移動設備，為成功進行胰島素治療所需的持續監測和計算提供決策支持。

此外，市場按設備類型分為手持設備和可穿戴設備。由於可穿戴數字糖尿病管理設備具有可訪問性、可擴展性和隨處測試等優勢，可穿戴設備的市場份額最大。諸如引入人工智能、增加採用自我管理的胰島素輸送設備、閉環泵系統和智能胰島素貼片等技術進步正在上升。

區域分析

北美在數字糖尿病管理全球市場中佔有最大份額

按地區劃分，全球數字糖尿病管理市場分為北美、南美、歐洲、亞太地區、中東和非洲。在所有地區中，由於糖尿病的高發病率，北美在全球數字糖尿病管理市場中佔據主導地位。根據美國糖尿病協會 (ADA) 的數據，每年約有 150 萬美國人被診斷出患有糖尿病。到 2022 年，大約 3730 萬人或美國人口的 11.3% 將患有糖尿病。預計數字糖尿病管理產品開發的技術進步將刺激市場。有利的報銷政策和更好的醫療保健設施的存在將推動市場的增長。

由於糖尿病患者的增加，預計亞太地區市場將出現積極擴張。根據亞洲糖尿病預防倡議，全球 60% 的糖尿病患者生活在亞洲（2020 年）。印度和中國等新興國家在亞洲的糖尿病患病率很高。中國約有 1390 萬成年人，即成年人口的 11.6%，患有糖尿病。印度約有 6510 萬成年人患有糖尿病。到 2030 年，中國和印度預計將有近 5 億糖尿病患者。一些組織、團體和研究機構正在提高對糖尿病患者的管理、診斷和治療的認識。技術進步、醫療保健投資的增加以及研發活動的增加預計將刺激市場增長。

競爭格局

由於存在多個國際和國內市場，全球數字糖尿病管理市場競爭激烈。產品多樣化、創收和機會使市場更具競爭力。Medtronic Plc、F. Hoffmann-La Roche Dexcom, Inc.、Abbott Laboratories、B. Braun Melsungen AG、Lifescan, Inc.（Subsidiary of Johnson &Johnson）和 Agamatrix, Inc. 是主要的市場參與者，擁有重要的市場份額。

公司利用新產品發布、產品開發、市場擴張和技術進步的戰略來維持其在市場中的地位。

公司正在開展合作、合併、戰略夥伴關係和收購，以增加對數字糖尿病管理的需求並在全球範圍內擴張。例如，2019 年 9 月，Medtronic與Novo Nordisk合作，提供結合各自技術的數字解決方案，幫助糖尿病患者更好地管理健康。根據協議，Medtronic的連續血糖監測（CGM）設備，包括 Guardian Connect 系統，將整合目前與Novo Nordisk共同開發的智能胰島素筆的胰島素劑量數據。

2022年7月，提供胰島素輸送和糖尿病相關技術的Tandem Diabetes Care宣布收購輸液器開發商Capillary Biomedical。

8 月，無內胎胰島素泵技術的領導者 Insulet Corporation 宣布美國 FDA 批准 Omnipod 5，這是一種用於 2 歲及以上患有 1 型糖尿病的兒童的自動胰島素輸送系統。

每家公司都籌集和投資以提高市場滲透率。例如，2020 年 1 月，Virta 籌集了 9300 萬美元的 C 輪融資，以擴大其數字糖尿病產品和覆蓋範圍。

值得關注的重點公司

Medtronic Plc：

概述 Medtronic plc 是一家總部位於美國明尼阿波利斯的製造和銷售醫療器械的美國公司。它在大約 140 個國家開展業務，擁有 90,000 名員工。

產品介紹

I-PORT ADVANCE：這是一個在皮下留有套管的注射口，因此插入時沒有疼痛，並且可以每三天注射一次藥物，只需少量穿刺。大人小孩都可以使用。

重大發展。2020年8月，醫療技術領導者Medtronic宣布收購InPen製造商Companion Medical——唯一獲得美國FDA批准的智能胰島素筆系統。

全球數字糖尿病管理市場報告提供了大約 45 個以上的市場數據表、40 多個數字和 180 頁的內容。

目錄

第一章 調查方法和範圍

  • 調查方法
  • 調查目的和範圍

第二章市場定義和概述

第三章執行摘要

第四章市場動態

  • 市場影響因素
    • 促進者
      • 糖尿病患病率上升
      • 技術進步加快
    • 抑製劑
      • 用於糖尿病管理的數字設備成本高
    • 商機
    • 影響分析

第五章行業分析

  • 波特五力分析
  • 監管分析
  • 供應鏈分析
  • 定價分析

第 6 章按產品/服務分類

  • 設備
    • 智能血糖儀
    • 連續血糖監測 (CGM) 系統
    • 智能胰島素筆
    • 智能胰島素泵/閉環泵/智能胰島素貼片
  • 數字糖尿病管理應用程序
    • 糖尿病/血糖管理應用程序
    • 體重和飲食管理應用
  • 數據管理軟件和平台
  • 其他

第 7 章 按設備類型

  • 手持設備
  • 可穿戴設備

第 8 章最終用戶

  • 自我/家庭保健
  • 醫院和糖尿病診所
  • 學術/研究機構
  • 其他

第9章按地區

  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 意大利
    • 西班牙
    • 歐洲其他地區
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美地區
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 澳大利亞
    • 亞太其他地區
  • 中東/非洲

第 10 章 競爭格局

  • 主要發展和戰略
  • 公司股份分析
  • 產品/服務基準測試
  • 值得關注的重點公司名單

第十一章公司簡介

  • Medtronic Plc
    • 公司簡介
    • 產品和服務的組合和內容
    • 主要亮點
    • 財務摘要
  • F. Hoffmann-La Roche Dexcom, Inc.
  • Dexcom, Inc.
  • Ascensia Diabetes Care Holdings Ag.
  • Abbott Laboratories
  • B. Braun Melsungen AG
  • Tidepool
  • Glooko, Inc.
  • Lifescan, Inc.（Subsidiary of Johnson & Johnson）
  • Agamatrix, Inc.

第 12 章全球數字糖尿病管理市場-DataM

簡介目錄
Product Code: DMMD2392

Market Overview

Digital Diabetes Management Market size was valued US$ 11.84 billion in 2021 and is estimated to reach US$ 29.76 billion by 2029, growing at a CAGR of 13.65% during the forecast period (2022-2029).

Diabetes is a metabolic disease that occurs due to high level of blood sugar levels. The result of either the pancreas does not produce enough insulin, or the body cannot effectively use the insulin it produces. It is characterized by the increased thirst and urination, increased hunger, fatigue, blurred vision, numbness or tingling in the feet or hands, sores that do not heal, and unexplained weight loss. Obesity, high blood pressure, heart disease, depression, physical inactivity, and others increase the risk of developing diabetes. The digital diabetes management system is used for improving self-management and controlling diabetes by reducing the blood glucose level and sustaining lower blood glucose.

Market Dynamics

The global digital diabetes management market is growing due to several factors such as the rising prevalence of diabetics drives the market growth with a rising geriatric population, sedentary lifestyle, and obesity. and novel technological advances.

Rising prevalence of diabetes and various new technological advancements are expected to drive market growth.

The rising prevalence of diabetics drives the market growth with a rising geriatric population, sedentary lifestyle, and obesity. According to the International Diabetes Federation, approximately 463 million adults of age-groups 20-79 have diabetes worldwide. This number is expected to increase and reach up to 700 million by 2045.

The market is witnessing the launch and approval of novel digital diabetes products. For instance, in May 2022, Roche diabetes care launched Accu-Fine, pen needles that provides virtually painless and smooth process of insulin delivery. It aims to better diabetes management by making insulin delivery easier for diabetic patients.

In Jun 2022, Abbott is developing a novel biowearable that will monitor glucose & ketone levels continuously in 1 sensor. System has already received breakthrough device designation from U.S.FDA. that will make life easier of people with life-threatening conditions.

The market is dominated by the presence of technological advancement products, including continuous glucose monitors, the systems that combine both a pump and a monitor for algorithm-driven automation of insulin delivery, long-distance patient care products, and artificial pancreas. For instance, in Feb 2021, Medtronic announced it got CE Mark for InPen smart insulin pen that can be used for multiple daily injections and Guardian 4 sensor also received CE Mark that doesn't need fingersticks for diabetes treatment decisions. This now permits the integration of sensor with InPen or MiniMed 780G for continuous glucose monitoring.

High cost of diabetes management products is expected to hamper the market growth.

The market is hindered by the high cost of digital diabetes management products, including smartphone-connected insulin pumps, sensor-based continuous glucose monitors, Digital self-monitoring blood glucose meters, etc. Moreover, the presence of unfavorable reimbursement scenarios in few countries shall hamper the market growth. There are disparities in reimbursement policies that often result in non-compliance to treatment, especially in developing countries, including India and China.

Industry Analysis

The global digital diabetes management market provides in-depth analysis of the market based on various industry factors such as Porter's Five Forces, Regulatory Analysis, Supply Chain Analysis, Pricing Analysis.

Segment Analysis

Product & service segment is expected to hold the largest market share in global digital diabetes management market

The global digital diabetes management market is segmented on product & service types as devices, digital diabetes management apps, data management software & platforms, and services. The devices segment accounts for the highest market share. The device segment includes smart glucose meters, continuous glucose monitoring (CGM) systems, smart insulin pens, smart insulin pumps/closed-loop pumps & smart insulin patches. The continuous blood glucose monitoring systems account for the highest market share due to their compatibility with smart devices. The continuous blood glucose monitoring systems segment held the largest market share of just under 40.0% owing to their compatibility with smart devices that serve as display devices. Moreover, they can also be set to send custom alerts to patients when certain glucose thresholds are reached. Continuous glucose monitoring devices involved the use of a sensor that is inserted under the skin. It provides glucose reading every one to five minutes on the monitor. It is possible to send custom alerts to patients when certain glucose thresholds are reached through this device. The market is dominated by the availability of the US Food and Drug Administration (FDA) approved products, including the DexCom G4 Platinum, Medtronic Diabetes Guardian Real-Time, and Medtronic Diabetes MiniMed Paradigm Real-Time Revel, which is a combination continuous glucose monitor and insulin pump.

The smart insulin pen segment is expected to have positive market growth, with too many companies developing the smart insulin pen. There is an increase in the launch of the smart insulin pen. For instance, in Nov 2020, Medtronic launched its InPen device integrated with its guardian connect glucose monitoring system after its acquisition of Companion Medical. InPen is the first and only FDA-cleared solution comprised of the insulin injector pen with an intuitive smartphone app and bolus advisor using bluetooth technology. It is effective in tracking insulin doses, including priming. It automatically sends the data to the user's mobile device, providing decision support for the constant monitoring and calculating necessary for successful insulin therapy.

Further, the market is also classified based on device type as handheld devices and wearable devices. The wearable devices segment accounts for the largest market share owing to the higher adoption of wearable digital diabetes management devices because of their advantages, such as better accessibility, scalability, and the ability to test anywhere. There is growing technological advancement, including the introduction of artificial intelligence, the growing adoption of self-administering insulin delivery devices, and closed-loop pump systems and smart insulin patches.

Geographical Analysis

North America region holds the largest market share in the global digital diabetes management market

By region, the global digital diabetes management market is segmented into North America, South America, Europe, Asia-Pacific, Middle-East, and Africa. Among all of the regions, North America dominated the global digital diabetes management market due to the high prevalence of diabetes. According to the American Diabetes Association (ADA), approximately 1.5 million Americans are diagnosed with diabetes every year. Around 37.3 million people, or 11.3% of the US population, have diabetes in 2022. The growing technological advancement for the development of digital diabetes management products shall stimulate the market. The presence of favourable reimbursement policies and better healthcare facilities shall fuel the market growth.

The Asia Pacific region is expected to have positive market growth owing to the increasing prevalence of diabetics. According to the Asian Diabetes Prevention Initiative, 60% of the world's diabetic population lives in Asia (2020). Developing countries such as India and China have a high prevalence of diabetics in Asia. Around 13.9 million adults, i.e., 11.6% of the adult population, have diabetes in China. Approximately 65.1 million adults with diabetes in India. It is expected that both China and India would have almost half a billion diabetic patients by 2030. Several organizations, associations, and institutes create awareness regarding the management, diagnosis, and treatment of diabetics. The growing technological advancement, rising healthcare investment, and increasing research and development activities shall stimulate market growth.

Competitive Landscape

The global digital diabetes management market is highly competitive with the presence of several international and local markets. Product diversification, revenue generation, and opportunities intensify the market competition. Medtronic Plc, F. Hoffmann-La Roche Dexcom, Inc., Abbott Laboratories, B. Braun Melsungen AG, Lifescan, Inc. (Subsidiary of Johnson & Johnson), and Agamatrix, Inc. are the leading market players with significant market share.

Companies are using the new product launch, product development, market expansion, and technological advancement strategies for holding their market position.

The companies are entering into collaborations, mergers, strategic partnerships, and acquisitions to increase the demand for digital diabetes management and their expansion across the globe. For instance, In September 2019, Medtronic had entered into a collaboration with Novo Nordisk to provide digital solutions that would combine their respective technologies to help diabetic patients better manage their condition. Under the terms of the agreement, Medtronic's continuous glucose monitoring (CGM) devices, including the Guardian Connect system, would integrate insulin dosing data from smart insulin pens currently in development with Novo Nordisk.

In Jul 2022, Tandem Diabetes Care, Inc., insulin delivery as well as diabetes technology company announced its acquisition of Capillary Biomedical, an infusion set developer.

In Aug 2022, Insulet Corporation, leader in tubeless insulin pump technology announced U.S. FDA clearance for automated Omnipod 5 insulin delivery system for children aged 2 years or above having type 1 diabetes.

The companies are raising the funding and investment to increase their market penetration. For instance, in January 2020, Virta had raised the USD 93 million Series C financing for increasing the reach of the digital diabetes product and reach.

Key Companies to Watch

Medtronic Plc:

Overview: Medtronic plc is an American company that operates in U.S. and manufactures and markets medical device headquarters in Minneapolis, US. It is operational in around 140 countries and 90,000 people are employed there.

Product Portfolio:

I-PORT ADVANCE: It is an injection port with painless insertion, as it leaves cannula under skin and with fewer punctures medications can be injected in every 3 days. It can be used by adults as well as children.

Key Developments: In Aug 2020, Medtronic, medical technology leader announced its acquisition of Companion Medical, InPen manufacturer- only U.S.FDA approved smart insulin pen system.

The global digital diabetes management market report would provide an access to an approx. 45+market data table, 40+figures and 180pages.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers:
      • 4.1.1.1. Rising prevalence of diabetes
      • 4.1.1.2. Increasing technological advancements
    • 4.1.2. Restraints:
      • 4.1.2.1. High cost of digital diabetes management devices
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Regulatory Analysis
  • 5.3. Supply Chain Analysis
  • 5.4. Pricing Analysis

6. By Product & Service

  • 6.1. Introduction
    • 6.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product & Service Segment
    • 6.1.2. Market Attractiveness Index, By Product & Service Segment
  • 6.2. Devices
      • 6.2.1.1. Introduction
      • 6.2.1.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
      • 6.2.1.3. Smart Glucose Meters
      • 6.2.1.4. Continuous Glucose Monitoring (CGM) Systems
      • 6.2.1.5. Smart Insulin Pens
      • 6.2.1.6. Smart Insulin Pumps/Closed-loop Pumps & Smart Insulin Patches
  • 6.3. Digital Diabetes Management Apps
    • 6.3.1. Diabetes & Blood Glucose Tracking Apps
    • 6.3.2. Weight & Diet Management Apps
  • 6.4. Data Management Software & Platforms
  • 6.5. Others

7. By Device Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Device Type Segment
    • 7.1.2. Market Attractiveness Index, By Device Type Segment
  • 7.2. Handheld Devices
      • 7.2.1.1. Introduction
      • 7.2.1.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 7.3. Wearable Devices

8. By End User

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User Segment
    • 8.1.2. Market Attractiveness Index, By End User Segment
  • 8.2. Self/Home Healthcare
      • 8.2.1.1. Introduction
      • 8.2.1.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 8.3. Hospitals & Specialty Diabetes Clinics
  • 8.4. Academic & Research Institutes
  • 8.5. Others

9. By Region

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 9.1.2. Market Attractiveness Index, By Region
  • 9.2. North America
    • 9.2.1. Introduction
    • 9.2.2. Key Region-Specific Dynamics
    • 9.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product & Service
    • 9.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Device Type
    • 9.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 9.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.2.6.1. U.S.
      • 9.2.6.2. Canada
      • 9.2.6.3. Mexico
  • 9.3. Europe
    • 9.3.1. Introduction
    • 9.3.2. Key Region-Specific Dynamics
    • 9.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product & Service
    • 9.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Device Type
    • 9.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 9.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.3.6.1. Germany
      • 9.3.6.2. U.K.
      • 9.3.6.3. France
      • 9.3.6.4. Italy
      • 9.3.6.5. Spain
      • 9.3.6.6. Rest of Europe
  • 9.4. South America
    • 9.4.1. Introduction
    • 9.4.2. Key Region-Specific Dynamics
    • 9.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product & Service
    • 9.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Device Type
    • 9.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 9.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.4.6.1. Brazil
      • 9.4.6.2. Argentina
      • 9.4.6.3. Rest of South America
  • 9.5. Asia Pacific
    • 9.5.1. Introduction
    • 9.5.2. Key Region-Specific Dynamics
    • 9.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product & Service
    • 9.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Device Type
    • 9.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 9.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.5.6.1. China
      • 9.5.6.2. India
      • 9.5.6.3. Japan
      • 9.5.6.4. Australia
      • 9.5.6.5. Rest of Asia Pacific
  • 9.6. Middle East and Africa
    • 9.6.1. Introduction
    • 9.6.2. Key Region-Specific Dynamics
    • 9.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product & Service
    • 9.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Device Type
    • 9.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User

10. Competitive Landscape

  • 10.1. Key Developments and Strategies
  • 10.2. Company Share Analysis
  • 10.3. Product & Services Benchmarking
  • 10.4. List of Key Companies to Watch

11. Company Profiles

  • 11.1. Medtronic Plc
    • 11.1.1. Company Overview
    • 11.1.2. Product & Service Portfolio and Description
    • 11.1.3. Key Highlights
    • 11.1.4. Financial Overview
  • 11.2. F. Hoffmann-La Roche Dexcom, Inc.
  • 11.3. Dexcom, Inc.
  • 11.4. Ascensia Diabetes Care Holdings Ag.
  • 11.5. Abbott Laboratories
  • 11.6. B. Braun Melsungen AG
  • 11.7. Tidepool
  • 11.8. Glooko, Inc.
  • 11.9. Lifescan, Inc. (Subsidiary of Johnson & Johnson)
  • 11.10. Agamatrix, Inc.

LIST NOT EXHAUSTIVE

12. Global Digital Diabetes Management Market - DataM

  • 12.1. Appendix
  • 12.2. About Us and End User
  • 12.3. Contact Us